19th Feb 2015 11:00
LONDON (Alliance News) - Ergomed PLC Thursday said it has signed a co-development agreement for sickle-cell disease treatment with Swedish drug development company Dilaforette AB, a company in which it will co-invest.
Dilaforette, a company owned by Karolinska Development AB, is developing sevuparin, a drug designed to restore blood flow and prevent further microvascular obstruction in both sickle cell disease and malaria patients.
In Thursday's statement, Ergomed said the phase II study in sickle-cell disease patients suffering from acute Vaso-Occlusive Crisis, is planned to start in the second quarter of this year.
"Ergomed will furthermore co-invest a proportion of its revenues from the clinical and regulatory activities of the trial in return for an equity stake in Dilaforette," Ergomed said.
Ergomed shares were trading 4.5% higher at 168.80 pence mid-morning Thursday.
By Rowena Harris-Doughty; [email protected]; @rharrisdoughty
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
ERGO.L